Arix Biosciences in strategic JV with Takeda Ventures
Shares in Arix Biosciences are down marginally after it unveiled a strategic agreement with Takeda Ventures Inc, which supported its initial public offering (IPO).
Arix Bioscience
142.00p
16:34 12/02/24
Financial Services
15,989.62
13:20 07/10/24
The agreement would maximise the complementary skills and experience of both companies across important therapeutic areas. Takeda invested in Arix's recent £100m IPO.
Healthcare and life sciences company Arix would provide Takeda with access to deal flow and a specialist team across its activities to create and incubate companies in partnership with Takeda.
This would be guided by a joint advisory committee comprising five appointees from both companies. Takeda had identified the fields of oncology and gastrointestinology as areas of particular interest to it.
At 10:48 GMT, shares in Arix were down 0.48% to 207p each.